ABOUT BIONICHE PHARMA
Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology.
The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in September 2010 by Mylan Inc. (Nasdaq; MYL), a Fortune 500 company that ranks as one of the world's leading generic and specialty pharmaceuticals companies, providing products to customers in more than 140 countries and territories. Mylan's acquisition of Bioniche Pharma provides the company with immediate entry into the North American injectables market and a platform for the commercialization of future biosimilar product offerings.
Within Mylan, Bioniche Pharma is part of Mylan Institutional, a newly created platform that provides differentiated pharmaceutical products to institutional customers throughout North America. Mylan Institutional's product offering includes the specialty injectables of Bioniche Pharma with the unit dose capabilities of Mylan's UDL Laboratories. Mylan Institutional's customers include group purchasing organizations, wholesalers, hospitals, surgical and radiology services, home infusion service providers, long-term care facilities, correctional facilities, specialty pharmacies, veterinary clinics and retail outlets.